The EORTC-1822 OligoCare cohort of the EORTC-1811 E²-RADIatE platform study, has now enrolled 250 patients!  

E²-RADIatE (EORTC 1811 study) is a platform that collects real-world data through prospective data registries in radiotherapy. A collaboration between the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO), it aims to be a pan-European infrastructure and a more efficient framework across the field of radiation oncology to generate robust data in cancer treatment and to further develop and integrate the discipline into therapeutic strategies.

OligoCare (EORTC 1822-RP) is collecting evidence for best practice in the radical (radiation) treatment of oligometastatic disease, where the cancer has metastasized to a limited number of organs. OligoCare is a pragmatic observational cohort study to evaluate radical radiotherapy for patients with oligometastatic disease. The main objective is to identify patient, tumour, diagnostic and treatment characteristics impacting overall survival.

For more information please visit: